Investor recruitment for BioTrinity 2014 is set to break all previous records. With 16 weeks to go, already 65 delegates from 50 VCs and Corporate Venture firms in ten countries have confirmed their participation. 

 

Do not miss this once-a-year opportunity to raise your profile with the investment community and meet firms with active funds. Presentation slots are filling up fast. If your company is seeking investment or partners, contact me now to secure one of the few remaining presentation slots. 

 

Similarly, if you are an investor with active funds under management, or have a portfolio company you'd like to see on the programme, contact me now to request an invitation to participate in another, game-changing BioTrinity.

Take the time to seize this opportunity and

Register Now for BioTrinity 2014.

BioTrinity 2014 is Europe's key conference for R&D companies raising investment - with more investors managing more capital accessible through a one-to-one partnering system than anywhere else, complemented by a select group of key investment advisors.

Participants from the Who's Who of European venture and US and European corporate venture attending BioTrinity include:

Margarita Chavez, Director, Venture Investments, AbbVie Biotech Ventures (USA)

Tim Haines, Partner, Abingworth (UK)

Raj Pareck,General Partner, Advent Venture Partners (UK)

Shawn Manning, Managing Director, Akesios Associates (UK)

Andrew Elder, Partner, Albion Ventures LLP (UK)

Andy Richards, Angel Investor

Allan Marchington, Partner, Apposite Capital (UK)

Brenig Preest, Investment Director, Arthurian Life Sciences (UK)

Stephane Mery, Partner, Beringea LLP (UK)

Ilka Wicke, Investment Manager / Director, Boehringer Ingelheim Venture Fund GmbH (Germany)

Ariel Jasie, Executive Director, Business Development, Celgene Corporation (USA)

Joseph Mason, Partner, Delta Partners (Ireland)

Lewis Bantin, Partner, ECI Partners (UK)

Olivier Litzka, Partner, Edmond de Rothschild Investment Partners  (France)

Dean Slagel, Managing Director, Esperante (Netherlands)

Melanie Goward, Deputy Fund Manager, Finance Wales (UK)

Sander van Deventer, General Partner, Forbion Capital Partners (Netherlands)

Ena Prosser, Partner, Fountain Healthcare Partners (Ireland)

Kevin Johnson, Partner, Index Ventures (UK)

Sacha Mann, Principal, Inventages Venture Capital (UK)

Saku Saha, Fund Manager, Invesco Perpetual (UK)

Mark Warne, Head of Life Sciences, IP Group plc (UK)

Jeanne Bolger, VP Venture Investing, Johnson & Johnson Development Corporation (USA)

Maurizio PetitBon, General Partner, Kreos Capital (UK)

Matthew Frohn, Partner, Longwall Ventures (UK)

Johan K�rdel, Senior Partner, Lundbeckfond Ventures (Denmark)

Mike Gutch, Managing Director, MedImmune Ventures  (USA)

Mark Payton, Managing Director, Mercia Fund Management (UK)

Reid Leonard, Managing Director, Merck Research Venture Fund (USA)

Andrew Muir, Investment Director, Midven (UK)

Jeffrey B. Moore, Vice President, MP Healthcare Venture Management (USA)

Jasper Bos, Director, MS Ventures (Switzerland)

Thomas Casdagli, Partner, MVM Life Science Partners (UK)

Dina Chaya, Partner, NeoMed (Switzerland)

David Mott, General Partner, New Enterprise Associates (USA)

Anja Koenig, Partner, Novartis Venture Funds (Switzerland)

Martin Edwards, Partner, Novo A/S (Denmark)

Henrijette Richter, Investment Director, Novo Seeds (Denmark)

Juliet Thompson, Partner, Oriel Securities (UK)

David Mott, Managing Partner & Co-Founder, Oxford Capital (UK)

Andrea Mica, Director, Oxford Technology (UK)

James Steel, Partner, Peel Hunt (UK)

Jonathan Hepple, Founder & Director, Rosetta Capital (UK)

Erin Lockwood, Managing Director, Silicon Valley Bank (UK)

Graziano Seghezzi, Partner, Sofinnova (France)

Marc d'Abbadie, Investment Director, SPARK Impact (UK)

Deborah Harland, Partner, SR One (UK)

David Phillips, Partner, SR One (UK)

Kate Bingham, Managing Partner, SV Life Sciences (UK)

Dinali de Silva, Associate, Synergis Technologies (UK)

Graeme Martin, President & CEO, Takeda Ventures (USA)

Mark Braganza, Principal, TPG Biotech (UK)

Ken Macleod, Partner, Visium Asset Management (UK)

Laia Crespo Martin, Investment Manager, Ysios Capital (Spain)